With clock ticking on Teva migraine drug, analyst expresses doubt for approval

7th September 2018 Uncategorised 0

Teva executives continue to express confidence the drugmaker’s novel migraine drug will get an FDA nod next week, but with questions lingering about the Celltrion manufacturing plant that will produce it, at least one analyst is writing it off for now.

More: With clock ticking on Teva migraine drug, analyst expresses doubt for approval
Source: fierce